New diabetes drug shows promise in phase 2 trial
NCT ID NCT07018453
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medication, SHR-3167, against a standard long-acting insulin (insulin degludec) in people with type 2 diabetes who already use basal insulin. The goal is to see which one controls blood sugar better and is safer. About 173 adults aged 18-65 with type 2 diabetes for at least 6 months are taking part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400000, China
-
Zhongshan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?
- Could a common diabetes drug weaken your bones?
- Can a spice and a mindset shift ease diabetic nerve pain?
- Ancient wisdom meets modern care: could chinese medicine boost diabetes Self-Management?
- Could a peptide injection help rebuild Insulin-Making cells?
- A pill for diabetes? new oral drug aims to rival injections